Prof. Dollar schreef op 6 maart 2015 09:46:
Synpromics announces new project with uniQure N.V.Synpromics Limited, a leading synthetic biology company, is pleased to announce that it has formed a collaboration with uniQure N.V., a world leader and pioneer in human gene therapy, to develop synthetic promoters with specific application in the delivery of gene medicines to liver.
Synpromics will use its unique approach to develop synthetic promoters with up- regulated, liver cell specific, activity whilst also decreasing the promoter molecular size to optimize the packaging efficiency of AAV.
The work is also supported by Scottish Enterprise through a grant awarded from its SMART: SCOTLAND scheme, which provides financial support to Small to Medium Enterprises across Scotland.
Dr David Venables, CEO of Synpromics, commented, “Synpromics are very pleased to undertake this collaboration with uniQure, and have a further opportunity to demonstrate the utility of our synthetic promoter technology to gene therapy applications. We have now advanced several projects in different areas and this collaboration highlights that our technology is being increasingly validated.”
Bekijk ook:
www.synpromics.com/